A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker.

Trial Profile

A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs DSP 3025 (Primary)
  • Indications Allergic asthma; Allergic rhinitis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 23 May 2012 Endpoint "Optimal-biological-dose" has not been met according to results presented at the 108th International Conference of the American Thoracic Society.
    • 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
    • 09 May 2012 Actual end date changed from Mar 2011 to Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top